Trial · NCT03390504
Adverse events1,096
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,096
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 40 | 142 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 39 | 117 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 51 | 173 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 44 | 173 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 1 | 142 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 15 | 117 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 5 | 173 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 0 | 173 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 0 | 142 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 24 | 117 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 3 | 173 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 1 | 173 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 4 | 142 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 9 | 117 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 13 | 173 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 12 | 173 | |
| other | Hyperparathyroidism | Endocrine disorders | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 8 | 142 | |
| other | Hyperparathyroidism | Endocrine disorders | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 0 | 117 | |
| other | Hyperparathyroidism | Endocrine disorders | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 4 | 173 | |
| other | Hyperparathyroidism | Endocrine disorders | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 0 | 173 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03390504/events